A Phase 1 interventional study of Apremilast IR and Apremilast XL in Healthy Volunteers, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-22.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the relative bioavailability of apremilast once-daily formulation relative to a twice daily formulation when administered as multiple doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part 2). Information on safety and tolerability will also be obtained.
Part 1: This is an open-label, randomized, two-period, two-sequence, crossover study in healthy subjects. The study will consist of a screening phase, a baseline phase, two treatment periods, and a follow-up phone call. Each period will be ten days in duration including 7 days of dosing and sample collection for up to 72 hours post Day 7 morning dose. There will be a washout between period 1 and period 2.
Part 2: This is an open-label, randomized, four-period, four-sequence crossover study to evaluate the PK and exposure of apremilast following single dose administration of different formulations of apremilast. Part 2 will consist of a screening phase, baseline, four treatment periods, and a follow-up phone call. Each period will be four days in duration for dosing (Day 1) and sample collection for up to 72 hours post Day 1.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study (Part 1 and Part 2):
Female subjects
Requirements:
Must comply with the following acceptable forms of contraception. All Female of child bearing potential (FCBP)1 must use one of the approved contraceptive options as described below while taking apremilast and for at least 28 days after administration of the last dose of the apremilast. At the time of study entry, and at any time during the study when a FCBP's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.
All FCBP must have a negative pregnancy test at Screening and Day -1 of each Treatment Period. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); Plus one additional barrier(c) contraceptive sponge with spermicide.
Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex or non-latex condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while on Product (IP) and for at least 28 days after the last dose of IP.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
1 A female of is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.
Drug: Apremilast IR · Drug: Apremilast XL
Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.
Drug: Apremilast IR · Drug: Apremilast XL
Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal.
Drug: Apremilast IR · Drug: Apremilast XL
Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal.
Drug: Apremilast IR · Drug: Apremilast XL
Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions.
Drug: Apremilast IR · Drug: Apremilast XL
Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions.
Drug: Apremilast IR · Drug: Apremilast XL
Apremilast immediate release tablet
Also known as: Otezla®
Apremilast extended release formulation tablet
Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast
Time frame: Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.
Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast
Time frame: Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.
Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast
Time frame: Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.
Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast
Time frame: Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.
Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast
Time frame: Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.
Number of Participants With Treatment-emergent Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. A serious AE is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.
Time frame: Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.
This study was conducted at 2 clinical sites in the United States. The study consisted of 2 parts. Part 1 was a multiple-dose two-period, two-sequence, crossover study. Part 2 was a four-period, four-sequence crossover study. Both parts enrolled healthy volunteers.
| Milestone | Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD | Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID | Part 2: Sequence 1 | Part 2: Sequence 2 | Part 2: Sequence 3 | Part 2: Sequence 4 |
|---|---|---|---|---|---|---|
| Started | 62 | 62 | 5 | 5 | 5 | 5 |
| Completed | 32 | 37 | 4 | 4 | 5 | 5 |
| Not completed | 30 | 25 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 4 | 4 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Discharged early due to hurricane | 22 | 20 | 0 | 0 | 0 | 0 |
| Withdrew: Other - miscellaneous | 1 | 0 | 0 | 0 | 0 | 0 |
| ng/mL | Part 1: Apremilast 30 mg IR BID | Part 1: Apremilast 75 mg XL QD |
|---|---|---|
| Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast | 451 ± 49.0 | 459 ± 35.0 |
| ng*hr/mL | Part 1: Apremilast 30 mg IR BID | Part 1: Apremilast 75 mg XL QD |
|---|---|---|
| Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast | 6370 ± 51.2 | 6090 ± 46.1 |
| ng/mL | Part 2: Apremilast 30 mg IR BID (Fasted) | Part 2: Apremilast 75 mg XL (Fasted) | Part 2: Apremilast 75 mg XL (Standard Meal) | Part 2: Apremilast 75 mg XL (High Fat Meal) |
|---|---|---|---|---|
| Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast | 379 ± 29.9 | 402 ± 32.5 | 436 ± 33.2 | 496 ± 25.2 |
| ng*h/mL | Part 2: Apremilast 30 mg IR BID (Fasted) | Part 2: Apremilast 75 mg XL (Fasted) | Part 2: Apremilast 75 mg XL (Standard Meal) | Part 2: Apremilast 75 mg XL (High Fat Meal) |
|---|---|---|---|---|
| Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast | 7030 ± 31.5 | 6650 ± 42.5 | 7580 ± 31.1 | 7400 ± 31.1 |
| ng*h/mL | Part 2: Apremilast 30 mg IR BID (Fasted) | Part 2: Apremilast 75 mg XL (Fasted) | Part 2: Apremilast 75 mg XL (Standard Meal) | Part 2: Apremilast 75 mg XL (High Fat Meal) |
|---|---|---|---|---|
| Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast | 7100 ± 31.4 | 6680 ± 42.4 | 7600 ± 31.1 | 7450 ± 31.1 |
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. A serious AE is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.
| Participants | Part 1: Apremilast 30 mg IR BID | Part 1: Apremilast 75 mg XL QD | Part 2: Apremilast 30 mg IR BID (Fasted) | Part 2: Apremilast 75 mg XL (Fasted) | Part 2: Apremilast 75 mg XL (Standard Meal) | Part 2: Apremilast 75 mg XL (High Fat Meal) |
|---|---|---|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 50 | 47 | 2 | 4 | 3 | 2 |
| TEAE related to study drug | 45 | 41 | 2 | 3 | 2 | 2 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 |
| Serious adverse events related to study drug | 0 | 0 | 0 | 0 | 0 | 0 |
| TEAE leading to discontinuation | 3 | 5 | 1 | 0 | 0 | 0 |
| TEAE related to study drug leading to discontinuation | 3 | 5 | 1 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Apremilast 30 mg IR BID | — | 0/108 (0%) | 41/108 (38%) |
| Part 1: Apremilast 75 mg XL QD | — | 0/107 (0%) | 35/107 (32.7%) |
| Part 1 Total | — | 0/124 (0%) | 59/124 (47.6%) |
| Part 2: Apremilast 30 mg IR (Fasted) | — | 0/20 (0%) | 2/20 (10%) |
| Part 2: Apremilast 75 mg XL (Fasted) | — | 0/19 (0%) | 4/19 (21.1%) |
| Part 2: Apremilast 75 mg XL (Standard Meal) | — | 0/18 (0%) | 3/18 (16.7%) |
| Part 2: Apremilast 75 mg XL (High Fat Meal) | — | 0/19 (0%) | 2/19 (10.5%) |
| Part 2 Total | — | 0/20 (0%) | 8/20 (40%) |
| Event | Part 1: Apremilast 30 mg IR BID | Part 1: Apremilast 75 mg XL QD | Part 1 Total | Part 2: Apremilast 30 mg IR (Fasted) | Part 2: Apremilast 75 mg XL (Fasted) | Part 2: Apremilast 75 mg XL (Standard Meal) | Part 2: Apremilast 75 mg XL (High Fat Meal) | Part 2 Total |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 27/108 | 25/107 | 43/124 | 0/20 | 1/19 | 2/18 | 2/19 | 5/20 |
| DiarrhoeaGastrointestinal disorders | 15/108 | 13/107 | 21/124 | 1/20 | 2/19 | 0/18 | 0/19 | 2/20 |
| NauseaGastrointestinal disorders | 11/108 | 7/107 | 16/124 | 1/20 | 1/19 | 0/18 | 2/19 | 3/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/108 | 8/107 | 15/124 | 0/20 | 0/19 | 0/18 | 0/19 | 0/20 |
| VomitingGastrointestinal disorders | 2/108 | 3/107 | 5/124 | 1/20 | 0/19 | 0/18 | 1/19 | 2/20 |
| DizzinessNervous system disorders | 2/108 | 2/107 | 4/124 | 1/20 | 1/19 | 0/18 | 0/19 | 2/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/108 | 7/107 | 8/124 | 0/20 | 0/19 | 0/18 | 0/19 | 0/20 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/108 | 3/107 | 8/124 | 0/20 | 0/19 | 0/18 | 0/19 | 0/20 |
| FatigueGeneral disorders | 5/108 | 5/107 | 7/124 | 0/20 | 0/19 | 0/18 | 0/19 | 0/20 |
| DyspepsiaGastrointestinal disorders | 3/108 | 0/107 | 3/124 | 1/20 | 0/19 | 1/18 | 0/19 | 1/20 |
All enrolled participants
| Age, Continuous(years) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Mean | 37.8 (19 to 55) | 34.7 (20 to 53) | 37.4 (19 to 55) |
| Sex: Female, Male(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Female | 46 | 7 | 53 |
| Male | 78 | 13 | 91 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 52 | 8 | 60 |
| Not Hispanic or Latino | 72 | 12 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Black or African American | 47 | 10 | 57 |
| White | 70 | 10 | 80 |
| Asian | 4 | 0 | 4 |
| Other | 2 | 0 | 2 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
No publications or documents are linked to this record.
Ran from Aug 2016 to primary completion in Nov 2016, 3 months.
Results were first posted in Jul 2021, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast